Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk
Authors
Keywords
-
Journal
DRUGS & AGING
Volume 37, Issue 8, Pages 551-558
Publisher
Springer Science and Business Media LLC
Online
2020-06-08
DOI
10.1007/s40266-020-00775-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
- (2020) Pablo Olivera et al. GASTROENTEROLOGY
- Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study
- (2020) Jeffrey D McCurdy et al. INFLAMMATORY BOWEL DISEASES
- JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function
- (2020) Susanne Adam et al. Science Translational Medicine
- Selective Janus kinase inhibitors come of age
- (2019) John J. O’Shea et al. Nature Reviews Rheumatology
- Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis
- (2019) Peter C. Taylor et al. Arthritis & Rheumatology
- Janus kinases to jakinibs: from basic insights to clinical practice
- (2019) Massimo Gadina et al. RHEUMATOLOGY
- Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials
- (2019) Wenhui Xie et al. ANNALS OF THE RHEUMATIC DISEASES
- Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
- (2019) Ben Klünder et al. CLINICAL PHARMACOKINETICS
- Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
- (2018) Massimo Gadina et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients
- (2018) Blas Y. Betancourt et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
- (2018) Josef S. Smolen et al. JOURNAL OF RHEUMATOLOGY
- Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: A cohort study of rheumatoid arthritis patients
- (2018) Rishi J. Desai et al. Arthritis & Rheumatology
- Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study
- (2017) Alexis Ogdie et al. EUROPEAN HEART JOURNAL
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Network pharmacology of JAK inhibitors
- (2016) Devapregasan Moodley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis
- (2016) Fawziah Marra et al. Open Forum Infectious Diseases
- Mechanisms and pathways of innate immune activation and regulation in health and cancer
- (2015) Jun Cui et al. Human Vaccines & Immunotherapeutics
- A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases
- (2014) Jason J Lee et al. ARTHRITIS RESEARCH & THERAPY
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study
- (2013) Wei-Sheng Chung et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease
- (2013) Sriram Krishnaswami et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study
- (2012) Hyon K Choi et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis and Association With Disease Duration and Hospitalization
- (2012) Marie E. Holmqvist et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now